What is Letybo and how does it compare to Botox and Dysport?

Letybo is a botulinum toxin product from South Korean manufacturer Hugel Aesthetics, now being rolled out in the U.S. market with a dedicated sales force. It's positioned as an alternative to Allergan's Botox and Galderma's Dysport, with branding around Korean aesthetic standards. Practices should evaluate Letybo's pricing against existing loyalty programs like Alle and Aspire as the product scales.

Why is Hugel investing in a U.S. direct sales force for toxins?

Hugel is building commercial infrastructure to compete directly with Allergan and Galderma in the North American aesthetic injectables market, which has been historically dominated by these two players. The investment signals serious commitment to U.S. market penetration and suggests potential pricing competition and rebate opportunities for practices.

What is the K-TOX campaign and what does it mean for medspa owners?

K-TOX is Hugel's branding campaign designed to build U.S. market recognition around Korean aesthetic techniques and standards. For medspa owners, it represents a new competitor entering the toxin category, which could create negotiating leverage on pricing and loyalty program terms with existing suppliers.

Should I switch to Letybo or add it as a second toxin supplier?

Hugel's U.S. expansion creates an opportunity to evaluate Letybo's pricing and rebate structures against your current Botox or Dysport agreements. Many practices benefit from dual sourcing to negotiate better terms; monitor Letybo's pricing relative to Alle and Aspire programs before committing to a switch.

How does Hugel's market entry affect toxin pricing and rebate programs?

A credible third competitor with direct U.S. sales infrastructure typically increases pricing competition and creates opportunities for practices to negotiate better rebate programs or volume discounts. Hugel's established international presence with Letybo suggests they have supply chain maturity, making them a viable alternative for practices seeking leverage in negotiations.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Business & M&A

Hugel Aesthetics Builds U.S. Footprint with Direct Sales Force for Letybo and K-TOX Campaign

South Korean manufacturer invests in commercial infrastructure to challenge Allergan and Galderma in the U.S. toxin market.

By Evan at Inside MedSpa · Jul 25, 2026

1-YEAR MOVE

ABBV ▲11.6%

1-year price move by ticker
Ticker	Company	1-year change
ABBV	AbbVie (Allergan Aesthetics)	+11.6%

Hugel Aesthetics announced expansion of its U.S. presence through a dedicated direct sales force for Letybo (its botulinum toxin product) and a new K-TOX campaign aimed at building brand recognition. The investment signals Hugel's commitment to competing directly in the North American aesthetic injectables market, historically dominated by AbbVie/Allergan and Galderma.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/hugel-aesthetics-us-expansion-letybo-direct-sales/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →

Hugel Aesthetics Builds U.S. Footprint with Direct Sales Force for Letybo and K-TOX Campaign

Share

Discussion

Leave a comment

By the time it's news, it's too late.